ReviewIUBMB life2013
The regulation and function of microRNAs in kidney diseases.
Review in IUBMB life, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 104 citations in OpenAlex.
- Fetuin-A and Heme Oxygenase 1 as Potential New Markers in the Diagnosis of Diabetic Kidney Disease.International journal of molecular sciences · 2025Review
- MiR-192-5p targets cell cycle regulation in diabetic kidney disease via cyclin-dependent kinase inhibitor 3.Non-coding RNA research · 2025Article
- Insights into non-coding RNAS: biogenesis, function and their potential regulatory roles in acute kidney disease and chronic kidney disease.Molecular and cellular biochemistry · 2025Review
- Physiological and cellular mechanisms of ischemic preconditioning microRNAs-mediated in underlying of ischemia/reperfusion injury in different organs.Molecular and cellular biochemistry · 2025Review
- New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.Genes & diseases · 2024Review
- Therapeutic potential of melatonin in targeting molecular pathways of organ fibrosis.Pharmacological reports : PR · 2024Review
- Lupus Nephritis Biomarkers: A Critical Review.International journal of molecular sciences · 2024Review
- MircroRNA-92b as a negative regulator of the TGF-β signaling by targeting the type I receptor.iScience · 2023Article
- Mesenchymal stem cells ameliorate cisplatin-induced acute kidney injury via let-7b-5p.Cell and tissue research · 2023Article
- Article
- Article
- Article
- Novel Translational Approaches To Study Kidney Disease.Journal of visualized experiments : JoVE · 2022Article
- Angiotensin (1-7) protects against renal ischemia-reperfusion injury via regulating expression of NRF2 and microRNAs in Fisher 344 rats.American journal of physiology. Renal physiology · 2022Article
- Identifying the molecular mechanisms of sepsis-associated acute kidney injury and predicting potential drugs.Frontiers in genetics · 2022Article
- Urinary microRNAs as non-invasive biomarkers for toxic acute kidney injury in humans.Scientific reports · 2021Article
- Non-coding RNAs and the mineralocorticoid receptor in the kidney.Molecular and cellular endocrinology · 2021Review
- Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences.International journal of molecular sciences · 2021Review
- Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy.Clinical kidney journal · 2021Article
- Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
MicroRNAs (miRNA) are endogenous short noncoding RNAs, which regulate virtually all major cellular processes by inhibiting target gene expression. In kidneys, miRNAs have been implicated in renal development, homeostasis, and physiological functions. In addition, miRNAs play important roles in the pathogenesis of various renal diseases, including renal carcinoma, diabetic nephropathy, acute kidney injury, hypertensive nephropathy, polycystic kidney disease, and others. Furthermore, miRNAs may have great values as biomarkers in different kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.